According to the website Seeking Alpha, Brean Capital maintained its “buy” rating and raised the price target on Celldex Therapeutics Inc. to $35 from $25 per share, based on encouraging data about the experimental drug CDX-1127 to treat lymphoma. “Given the clean safety of CDX-1127, we believe combining CDX-1127 with other agents would be the path forward with CDX-1127 . . . and believe that auto immunelike toxicities that may emerge when combining CDX-1127 with another immune-stimulating agent can be managed,” analyst Jonathan Aschoff wrote.
Analyst raises price target for Celldex
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week